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 CURRENTOPINION Progress in the therapy of myasthenia gravis:
getting closer to effective targeted immunotherapies
Marinos C. Dalakasa,b
Purpose of review
To provide an update on immunomodulating and immunosuppressive therapies in myasthenia gravis and
highlight newly approved, or pending approval, therapies with new biologics.
Recent findings
Preoperative IVIg is not needed to prevent myasthenic crisis in stable myasthenia gravis patients scheduled
for surgery under general anesthesia, based on controlled data. Rituximab, if initiated early in new-onset
myasthenia gravis, can lead to faster and more sustained remission even without immunotherapies in 35%
of patients at 2 years. Biomarkers determining the timing for follow-up infusions in Rituximab-responding
AChR-positive patients are discussed. Most patients with MuSK-positive myasthenia gravis treated with
Rituximab have sustained long-term remission with persistent reduction of IgG4 anti-MuSK antibodies.
Eculizumb in the extension REGAIN study showed sustained long-term pharmacological remissions and
reduced exacerbations. Three new biologic agents showed promising results in phase-II controlled
myasthenia gravis trials: Zilucoplan, a subcutaneous macrocyclic peptide inhibiting complement C5;
Efgartigimod, an IgG1-derived Fc fragment binding to neonatal FcRn receptor; and Rozanolixizumab, a
high-affinity anti-FcRn monoclonal antibody. Finally, the safety of ongoing myasthenia gravis
immunotherapies during COVID19 pandemic is discussed.
Summary
New biologics against B cells, complement and FcRn receptor, are bringing us closer to successful targeted
immunotherapies in the chronic management of myasthenia gravis promising an exciting future for
antibody-mediated neurological diseases.
Keywords
B cells, complement, myasthenia gravis immunotherapy, neonatal Fc receptor
INTRODUCTION
Myasthenia gravis remains the prototypic antibody-
mediated autoimmune disease with a gratifying
response to various nonspecific immunotherapies
if properly applied. At least 75% of the patients can
be successfully managed with a combination of
corticosteroids and a maintenance immunosuppres-
sant, whereas treatment with IVIg or plasmapheresis
are effective for severe cases or acute worsenings
[1
&&
,2–4]. For the chronic management of myasthe-
nia gravis, however, there are challenges. At least
15% of patients can be refractory or incompletely
responding to available therapies whereas in several
others, long-term steroids and immunosuppressants
are not well tolerated, especially with comorbidities,
necessitating the need for better therapies. New
biologics are now evolving into powerful tools
changing the algorithm or the timing of the various
therapeutic regimens promising clinical remission
with minimal long-term side effects.
The review provides an update on the current
therapies in the chronic management of generalized
myasthenia gravis highlighting the promising
results of emerging targeted immunotherapies,
approved or waiting approval after successful phase
II and III clinical trials.
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REVIEW
UNDERSTANDING TARGETED THERAPIES
BASED ON MYASTHENIA GRAVIS
IMMUNOPATHOGENESIS
As previously discussed [1
&&
], it is unclear what
triggers myasthenia gravis but, like other autoim-
mune disorders, the process begins when tolerance
is broken probably by infectious agents that share
sequence homologies with AChR resulting in cross-
reactivity and autoimmunity [1
&&
]. Unique to early-
onset AChR-positive myasthenia gravis, compared
with other autoimmune diseases, is the involve-
ment of the thymus that contains lymphoid germi-
nal centers overexpressing proinflammatory
cytokines and MHC-II-positive thymic epithelial
cells that present AChR subunits to CD4þ T cells
leading to upregulation of IL4 and IL6 that stimulate
B cells to produce anti-AChR antibodies [1
&&
,2].
AChR-specific CD4þ T cells, by producing IFN-g
and IL-17, support B-cell functions in response to
AChR stimulation while regulatory T- cells (Treg)
and Th17-cells enhance antibody production and
increase proinflammatory cytokines (1). The AChR
antibodies fix complement at the end-plate region
leading to destruction of the AChR’s and simplifica-
tion of the end-plates (Fig. 1).
Targeted immunotherapies in myasthenia
gravis involve drugs directed against molecules asso-
ciated with T-cell activation, B cells and antibodies,
complement, the neonatal Fc receptor of IgG anti-
bodies FcR (FcRn) affecting antibody catabolism,
and cytokines associated with antibody production
and impaired immunoregulation [1
&&
]. Significant
progress in the last 3 years have been made with
biologics-targeting B cells (1), complement (2)
and FcRN (3) (Fig. 1) offering very promising
therapeutic prospects.
IMMUNOTHERAPIES AS RELATED TO
CLINICAL SUBTYPES AND CIRCULATING
ANTIBODIES
The main myasthenia gravis subtypes requiring sys-
temic immunotherapies with steroids, steroid-spar-
ing immunosuppressants, IVIg or plasmapheresis
are patients with early-onset generalized myasthe-
nia gravis (EOMG), when the disease starts before
the age of 50 years and peaks in the 40s, and late-
onset generalized myasthenia gravis (LOMG) start-
ing in the 60s and peaking in the 70s [1
&&
,2–6]. These
patients invariably present with weakness in the
extraocular, facial, and bulbar muscles with diplopia
dysphagia and dysphonia, fatigable weakness in
neck and proximal limb muscles, and in severe
cases, involvement of the respiratory muscles. The
main differences in therapeutic decisions relate to:
consideration for thymectomy only in EOMG,
except for thymomas that require excision in all
MG subtypes; selecting a well tolerated immuno-
suppressant for women with EOMG planning preg-
nancy; consideration of comorbidities in LOMG
that influence the choice of medications and treat-
ment duration; and type of autoantibodies. Patients
with anti-AChR antibodies, detected in 85% of the
patients with the aforementioned phenotypes,
respond to the same therapies; this also applies to
6 to 8% of seronegative myasthenia gravis patients
who probably have low-affinity or low-titre anti-
AChR antibodies. In contrast, patients with anti-
bodies to Muscle-Specific-Kinase (MuSK), behave
therapeutically differently. Anti-MuSK antibodies
are of the IgG4 subclass and do not fix complement,
not responding to anticomplement therapeutics as
discussed below. Further, their thymus lacks histo-
logical alterations, not requiring thymectomy, and
do not respond to antianticholinesterases.
STARTING AND MAINTAINING
IMMUNOTHERAPY: WHAT IS NEW
MG is a chronic disease requiring prolonged use of
corticosteroids and immunosuppressants or immuno-
modulators.A step-by-step therapy remainsas follows:
Anticholinesterases
Pyridostigmine, 60 mg four times daily, remains the
earliest therapeutic step offering mild symptomatic
but transient help in AChR-antibody-positive myas-
thenia gravis.
Corticosteroids
It is the first-line drug starting with an escalation
dose of 20 mg daily increasing it – as needed – even
KEY POINTS
 Eculizizumab offers an effective, well tolerated and
sustained remission in chronic management of
myasthenia gravis.
 Ravulizumab (ALXN1210) seems a very promising
second generation eculizumab with long-lasting effect.
 Zilucoplan is the first subcutaneous anticomplement
agent effective in myasthenia gravis.
 Efgartigimod and Rozanolixizumab are the first
effective agents against FcR whereas Nipocalimab is in
the offing.
 Myasthenia gravis and the various immunotherapies do
not make the patients more susceptible to infections
during COVID-19 pandemic.
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up to 80–100 mg daily. Once stability is established,
usually after 6 weeks, slow tapering to every-other
day begins, aiming to reach the lowest possible dose
that controls the disease with minimal side-effects.
Immunosuppressants (Azathioprine,
Mycophenolate Mofetil, Cyclosporine,
Tacrolimus)
These drugs are used to facilitate reduction of pred-
nisone and maintain long-term stability, even
though their efficacy remains variable, inconclu-
sive, and not confirmed in large controlled studies.
As there are no evidence-based comparative studies,
the choice of selecting an immunosuppressant still
varies among practitioners, with most preferable
being mycophenolate 2000 mg daily (going up
3000, if needed) or Azathioprine (150 mg daily)
[1
&&
,2–4].
A number of recent studies have shown that
discontinuation or marked reduction of mycophe-
nolate increases the risk of myasthenia gravis exacer-
bation after 3 months supporting the view of
efficacy and the need for long-term administration
[7–10]. At least 30% of patients undergoing myco-
phenolate taper relapsed when the mean dose was
reduced to 888 mg/day or was tapered quickly (8.4
vs. 62.4 months in nonrelapsed) [7–10]. After sev-
eral years of disease stability; however, mycopheno-
late can be tapered provided the dose reduction is
FIGURE 1. The main players involved in the Immune Network of Myasthenia Gravis and key immunotherapeutic targets ()
related to ongoing trials. The AChR, presented via APCs to CD4þT cells via co-stimulatory molecules lead to upregulation of
cytokines that stimulate B cells to produce IgG anti-AChR antibodies, which, by fixing complement at the end-plate region,
lead to destruction of the AChRs. Treg and Th17þ cells, cytokines, such as IL-6 that affect the induction of Tregs, and
proinflammatory cytokines, such as IL-17A, IL-21, IL-22, are increased in myasthenia gravis patients sustaining the immune
imbalance. CD4 þ T cells via IL-4, IL6 cytokines facilitate antibody production by B cells, the soluble B-cell activation factor
(BAFF) promotes B-cell survival and maturation, whereas Treg and Th17þ cells affect antibody production via Th1/Th2
cytokine balance. The currently ongoing, and very promising, targeted therapies () are against: B cells (1); Complement
(2) which leads to destruction of AChR at the postsynaptic region when fixed by the anti-AChR antibodies; and FcRn (3),
leading to increased catabolism of IgG-AChR antibodies. Adapted with permission from Dalakas [1&&,6].
Progress in the therapy of myasthenia gravis Dalakas
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slow, not more than 500 mg/day every 12 months
[10]. My preference is even slower, tapering it by
250 mg yearly. Cyclosporine, up to 150 mg twice
daily, and Tacrolimus 0.1 mg/kg are two other
options in refractory myasthenia gravis based on
large and mostly uncontrolled series [11]. The effi-
cacy of Tacrolimus has now been strengthened with
a new controlled study [12] with evidence that it can
be successfully lowered, after long-term stability,
from 3 mg/day to almost 1 mg/day without exacer-
bations [13].
Intravenous immunoglobulin and
plasmapheresis: new data
For urgent relief in patients with severe disease and
significant worsening including crises, plasmaphe-
resis (every other day, six times) or intravenous
immunoglobulin (IVIg) 2 g/kg, remain the best
options [14]. Plasmapheresis may be more preferable
in a crisis acting faster but the choice between the
two is overall determined by practical issues such as
availability, age, comorbidities, venous access or
specialized hospital settings.
The effectiveness of IVIg in acute exacerbations
in myasthenia gravis patients requiring hospitaliza-
tion was again confirmed in a prospective uncon-
trolled phase-III study [15
&
]. A new prospective,
randomized, double-blind study in 47 stable myas-
thenia gravis patients, 25 randomized to IVIg and 22
to placebo, assessed whether IVIg can prevent myas-
thenia gravis crisis in stable patients scheduled for
surgery. The study showed that preoperative admin-
istration of IVIg is not needed in well controlled
patients scheduled for surgery under general anes-
thesia to prevent myasthenic crisis [16
&&
]. The study
is useful considering the frequent requests we
receive from surgeons or anesthesiologists whenever
general surgery is planned even on clinically stable
myasthenia gravis patients.
IVIg is extensively used as maintenance therapy
or as steroid-sparing agent, even though the scien-
tific merit (considering the short-lasting benefit),
cost, and long-term efficacy have not been estab-
lished. A retrospective analysis failed to show long-
term remission with IVIg [17,18]. The need to estab-
lish efficacy in the chronic management of myas-
thenia gravis led to two controlled trials that have
been completed (ClinicalTrials.gov NCT 02473952,
02473965), but not yet published. The same applies
to subcutaneous Immunoglobulin (SCIg). A pro-
spective, open-label, phase III trial in patients with
mild-to-moderate exacerbation (transition from
MGFA class I to II/III or class II to III), showed that
SCIg (2 g/kg), over 4 weeks, is well tolerated and
effective in reducing myasthenia gravis disability
measures [19,20]. SCIg ensures more consistent
serum IgG levels with reduced wearing-off effect
at the end of each treatment cycle, and although
it might be suitable for certain patients with poor
venous access or underlying risk factors, a compara-
tive study is needed to determine if it is as good or
more preferable to IVIg in maintaining remission.
Progress in target-specific biologic therapies
A number of biologics directed against key immune
molecules approved for various autoimmune dis-
eases (1), can also target the same molecules within
the myasthenia gravis immune network. The most
successful results today have been with agents
directed against: B-cells and autoantibodies (1);
complement (2); and the neonatal FcRn Receptors
(3) (Fig. 1), supporting the pathogenic role of auto-
antibodies in MG pathogenesis.
Agents against B cells
Bcells are involvednotonly incomplementactivation
and antibody production but also in antigen presen-
tationandcytokinerelease including IL-1, IL-6, andIL-
10 [21]. Accordingly, targeting B cells in myasthenia
gravis may restore immune balance [1
&&
,2–4].
Rituximab
This is the main anti-B-cell agent on the market,
approved for some systemic autoimmune diseases,
that has been extensively tried in myasthenia gravis.
Rituximab is a chimeric monoclonal antibody
against CD20, a 297 AA membrane-associated phos-
phoprotein present on all B cells, except stem cells,
pro-B cells, and plasma cells [1
&&
,2,21], that depletes
only circulating B cells but not B cells in the bone
marrow and lymph nodes [1
&&
,21,22].
On the basis of many uncontrolled studies, Rit-
uximab, 375 mg/m2 once a week for 4 weeks, or 2 g
(divided in two, 1 g each, biweekly infusions), has
been effective in 50–70% of myasthenia gravis
patients [22–28]. In a 10-year outcome, the data
seem remarkable regarding safety, sustained clinical
improvement, tapering of other immunotherapies,
in-hospital cost, and impact on childbearing poten-
tial [26]. The success is impressive in MuSK-MG [26–
28]; in a multicenter, blinded, prospective review,
58% (14/24) rituximab-receiving patients reached
the primary outcome compared with 16% (5/31)
of controls (P¼0.002), after a median follow-up of
3.5 years; further, 29% of rituximab-treated patients
required a mean-prednisone dose of 4.5 mg/day,
compared with 13 mg/day required by 74% of con-
trols (P¼0.001 and P¼0.005) [28].
In a phase II, placebo-controlled trial; however,
where 52 AChR-MG patients received two cycles of
Peripheral nerve and neuro-muscular junction disease
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rituximab separated by 6 months, the primary out-
come based on the proportion of patients achieving
greater than 75% reduction in the mean daily pred-
nisone dose after 48 weeks, was not met [29]. This
study was underpowered while the selected out-
come had low probability of showing effectiveness.
A new retrospective study with prospectively col-
lected data from 72 patients compared the effect or
rituximab in 24 patients treated early, within
12 months of disease onset, to 48 patients treated
at a later time when their disease was therapy refrac-
tory. The study conclusively showed that the
median time to remission was shorter for new-onset
vs. refractory disease after rituximab treatment com-
pared with conventional immunosuppressive ther-
apies; further, the first 24 months a larger
proportion of patients had had fewer relapses with
minimal or no need for additional immunothera-
pies. These results are compelling pointing out that
rituximab performs even better in new-onset gener-
alized myasthenia gravis being safer than conven-
tional immunosuppressants.
The need for follow-up infusions in responders
remains empirical as AChR-antibody measurements
and CD20þ B cells are unhelpful [22]. Some prefer a
repeated infusion when clinical relapse occurs;
others, use 2 g every 6 months or 1 g every 3 months
to ensure stability [21]. The most promising marker,
identified in other rituximab-responsive patients
with autoimmune diseases, is the reemergence of
CD27þmemory B cells [31,32]. In one uncontrolled
study, no myasthenia gravis relapses occurred when
the CD27þ memory B cells were below the thera-
peutic target, whereas their resurgence was associ-
ated with clinical relapses [33]. In contrast to AChR-
positive myasthenia gravis however, where rituxi-
mab has insignificant effect on AChR-antibody
titers [30
&&
,31–33], in Musk-MG there is marked
reduction of IgG4-Musk antibodies after 2–7
months [34
&
], coinciding with clinical remission
based on retrospective long-term (1.5–13 years) data
in nine Rituximab-treated patients [34
&
]. Most
patients had sustained improvement for several
years with IgG4-musk antibodies being even unde-
tectable within 2 years [34
&
]. In one patient, who did
not respond, MuSK-IgG4 antibodies remained
unchanged. The data support the view that short-
lived antibody-secreting cells are the main pro-
ducers of Musk antibodies.
Other anti-B-cell agents and third-
generation anti-CD20/CD19
Belimumab, against soluble BAFF, and Atacicept
against Blys, are effective in lupus erythematosus
[35]. As BAFF plays a role in myasthenia gravis (1), a
trial with Belimumab was completed in 39 AChR
and MuSK-positive patients; the drug was, however,
ineffective [36]. The newer agents include: Occreli-
zumab, a humanized monoclonal antibody against
CD20, approved for MS [37] but not yet tried in MG;
Ofatumumab that targets not only the large loop of
CD20 but also small epitopes closer to B-cell mem-
brane causing more effective B-cell lysis [37]. A
patient with refractory myasthenia gravis unrespon-
sive to IVIG, mycophenolate and rituximab normal-
ized after two ofatumumab infusions with sustained
depletion of circulating B lymphocytes [38]; Obinu-
tuzumab, a third-generation anti-CD20, approved
for chronic lymphocytic leukemia, causes profound
peripheral B-cell lysis, including lymphoid B cells
[1
&&
,35,37]. Obinutuzumab almost cured a myasthe-
nia gravis patient with CLL [39]; and Ublituximab,
another glycoengineered anti-CD20, currently in
phase-II MS trials, and Inebilizumab, an anti-
CD19 monoclonal that additionally targets pro-B
cells, plasmablasts, and some plasma cells, now
approved for NMOSD [37], may be future consider-
ations in refractory myasthenia gravis.
Anticomplement biologics
Eculizumab (Soliris)
This is a monoclonal antibody against complement
C5 that intercepts the formation of MAC fixed by
the AChR-antibodies at the end-plate (Fig. 1). Ecu-
lizumab is the first drug approved for refractory-
myasthenia gravis, that constitutes 10–15% of
myasthenia gravis patients, based on encouraging
results in a phase-2 study [40] that led to phase-III
randomized, 26-week trial (REGAIN). Statistically
significant improvements in MG-Activities of Daily
Living (MG-ADL) and Quantitative-MG (QMG)
scores from baseline to week 26 were noted in 62
eculizumab-randomized patients compared with 63
placebo-randomized ones [41]. Myasthenia gravis
exacerbations occurred in 10% of the eculizumab
group, compared with 24% in the placebo, whereas
10% of eculizumab-receiving patients required res-
cue therapy compared with 19% in the placebo.
Eculizumab is very expensive, but as its benefit is
noticeable within the first 4–8 weeks, unnecessary
costly administrations could be avoided early after
treatment initiation.
Patients completing REGAIN entered the open-
label extension (OLE) study in which 117 refractory-
myasthenia gravis patients were treated with
1200 mg eculizumab every 2 weeks for a mean
period of 22.7 months [42
&
]. The study showed
reduced exacerbation rate by 75%, maintenance
of improved functional abilities throughout a 3-year
period, and achievement of minimal manifestation
or pharmacological remission in 56% of patients
Progress in the therapy of myasthenia gravis Dalakas
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demonstrating long-term safety and sustained effi-
cacy [42
&
]. Another subgroup analysis from REGAIN
and OLE evaluating the response to eculizumab over
an 18-month period in patients receiving chronic
IVIg before participating in REGAIN, showed also
sustained eculizumab efficacy [43]. The placebo-
receiving patients in REGAIN experienced rapid
improvements in assessment scores when treated
with eculizumab in the OLE with lower exacerbation
rate compared with placebo.
Ravulizumab (Ultomiris)
Ravulizumab (ALXN1210), is a humanized mono-
clonal antibody functionally similar to eculizumab,
that binds with high affinity to C5 preventing the
generation of complement activation products C5a
and C5b-9 [44
&&
]. Ravulizumab provides a sustained
complement inhibition and has an increased half-
life relative to eculizumab requiring less frequent
dosing (once every 8 weeks, compared with once
every 2 weeks for eculizumab). Ravulizumab has
gained Food and Drug Administration (FDA)
approval for PNH. A phase III FDA-approved study
is currently ongoing in myasthenia gravis patients.
Zilucoplan
Zilucoplan is a synthetic, macrocyclic peptide that
binds C5 with sub-nanomolar affinity inhibiting its
cleavage into C5a and C5b intercepting MAC forma-
tion [44
&&
]. Zilucoplan is administered subcutane-
ously. In a phase 2 trial, 44 patients with
generalized myasthenia gravis received daily subcu-
taneous injection of either 0.3 mg/kg zilucoplan,
0.1 mg/kg zilucoplan or placebo over 12 weeks
[45
&&
]. Patients on the higher dose achieved a mean
reduction (from baseline) of 6 points in the QMG
score, compared with 3.2 reduction in the placebo
group, and 3.4 points reduction in the MG-ADL score
compared with 1.1 point on placebo (scores>6 sug-
gest that ADL are moderately/severely impacted by
the disease). No serious adverse effects were observed.
The rapid, meaningful, and sustained improvements
over 12 weeks implied that maximal complement
inhibition is necessary for pronounced disease sup-
pression, leading to an ongoing Phase III trial.
Modulation of Fc and neonatal Fc receptors
The neonatal Fc receptor (FcRn) is involved in IgG
transport and homeostasis and relates to IgG catab-
olism; antagonizing FcRn, results in rapid and sus-
tained reduction of IgG autoantibodies [1
&&
,46]. On
this basis, the following three drugs are now tested
in phase-III MG trials:
Efgartigimod (ARGX-113), an IgG1-derived Fc
fragment binding to FcRn was tested in a phase-II
randomized, double-blind, placebo-controlled, trial
in 24 myasthenia gravis patients on their standard-
of-care therapy [47
&&
]. Twelve patients received four
doses over a 3-week period of 10 mg/kg intravenous
efgartigimod and 12 placebo. Although the primary
endpoints were safety and tolerability, all patients
receiving efgartigimod showed a rapid, within
2 weeks after the last dose, decrease in the total
IgG and anti-AChR autoantibody levels; 75% of
patients showed a rapid and long-lasting improve-
ment in four efficacy scales coinciding with the
maximal IgG-lowering and reduction of AChR-anti-
body levels. The AChR-antibody levels returned to
normal within 8 weeks. The study concluded that
Efgartigimod was not only safe and well tolerated
but also effective leading to a phase III trial. This is
an exciting and novel therapeutic approach as it
does not cause widespread immunosuppression but
a seemingly safe and meaningful reduction of IgG
and AChR-antibody levels.
Rozanolixizumab, a high-affinity human anti-
FcRn IgG4 monoclonal antibody that results in
marked decreases in IgG concentrations (75–90%
from baseline). A phase II study was conducted in 43
AChR-positive and Musk antibody-positive gener-
alized myasthenia gravis patients, randomized to
three, once weekly, subcutaneous infusions of pla-
cebo or 7 mg/kg rozanolixizumab on days 1, 8, and
15 [48]. After 4 weeks, patients were re-randomized
to three doses of either 4 or 7 mg/kg rozanolixizu-
mab. Although, like efgartigimod, the primary out-
come was safety, a statistically significant
improvement in the MG-ADL score was noted in
the rozanolixizumab group, especially with the
high doses, without any difference in the rate of
infections between all groups [49]. A 68% decrease
in IgG and AChR autoantibodies were noted leading
to a phase III study.
Nipocalimab, a monoclonal antibody that binds
with picomolar affinity to FcRn. The drug allows
occupancy of FcRn throughout the recycling path-
way promising higher efficacy. A phase II study is
underway in myasthenia gravis with similar end-
points as Efgartigimod and Rozanolixizumab.
Other target-specific, biologic therapies in
myasthenia gravis trials
Other biologics, approved for various autoimmune
diseases, target the same key molecules within the
myasthenia gravis immune network (1) (Fig. 1).
Among them, the most relevant to myasthenia
gravis are the Janus Kinase (JAK) inhibitors (Tofaci-
tinib, Ruxolitinib, and Baricitinb directed against T-
cell signaling factors associated with antigen presen-
tation that suppress T and B cells while maintaining
Peripheral nerve and neuro-muscular junction disease
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Treg-cell function. Ruxolitinib has been effective in
MuSK-positive myasthenia gravis [49]. Agents
against cytokines and cytokine receptors targeting
IL-6 and IL-17 are relevant to pathogenesis of myas-
thenia gravis by affecting the induction of Tregs and
antibody production [50]. Of interest, Tocilizumab,
an IL6- receptor antagonist approved for rheuma-
toid arthritis, was effective in two refractory-myas-
thenia gravis patients resistant to rituximab and
IVIg [51].
Coronavirus disease-2019 and myasthenia
gravis immunotherapies
Although coronavirus disease-19 (COVID-19) infec-
tion, like most other viruses, can potentially worsen
patients with preexisting autoimmunity like myas-
thenia gravis, there is no evidence that myasthenia
gravis patients stable on common immunotherapies
are more susceptible to COVID-19. If clinically sta-
ble and not lymphopenic, there is no compelling or
data-driven reasons to change any of the immuno-
suppressive therapies they are receiving and disturb
clinical stability [52
&
]. For patients on monthly IVIg,
there may be even a theoretical advantage that IVIg
offers additional protection because of natural auto-
antibodies; if IVIg is not infused as home infusion,
switching to self-administered subcutaneous IgG
might be an option to diminish exposure [52
&
].
For patients on rituximab, the infusion intervals
can be prolonged to more than 6 months, because
both, B-cell reduction and clinical benefit, can per-
sist longer [21,35]. Just published data suggest pos-
sible beneficial effect of anticomplement therapies
[52
&
,53]. Complement is an integral component of
the innate immune response to viruses with evi-
dence that C3 activation exacerbates SARS-CoV-
associated ARDs; further, lung biopsies from
COVID-19 patients show abundant complement
deposits [53]. It was proposed that complement
inhibition may alleviate the inflammatory compli-
cations of COVID-19 and on this basis, eculizumab
is undergoing a trial for ARD [52
&
,53]. Theoretically,
therefore, eculizumab may even have added protec-
tion in myasthenia gravis. General suggestions were
also offered by the International MG/COVID-19
Working Group enhancing the view to continue
current treatments, including participation in the
ongoing FcRn trials, but follow standard precautions
[54].
CONCLUSION
Recent trials with rituximab and biologics targeting
complement and FcRn receptors are major steps
towards targeted immunotherapy in the chronic
management of myasthenia gravis. The results are
particularly important not only for myasthenia
gravis but also for other antibody-mediated neuro-
logical diseases as they demonstrate that suppress-
ing pathogenic autoantibodies can lead to sustain
remission. The effect of rituximab opens the way for
trials with other more effective third-generation
anti-B-cell agents currently on the market. The
exciting results from five clinical trials with new
biologic agents, three against complement and
two against FcRn receptor, are setting up the stage
for new agents now in the offing within this family
of drugs, promising even safer and more sustained
benefits confirming the prediction that ‘the future
of MG immunotherapies is not what used to be’ [55].
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